Clinical Trials Browser

Has results × Leukemia, Plasma Cell × Bortezomib × Clear all

NCT00307086 2017-03-06

Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants

Phase 2 Completed

30 enrolled 7 charts

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma